Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Riboflavin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.72 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 7/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.89 |
| ▸ | USP2 | O75604 | 4/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.89 |
| ▸ | HAT1 | O14929 | 4/20 | 0.89 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.89 |
| ▸ | HTT | P42858 | 4/20 | 0.89 |
| ▸ | RECQL | P46063 | 3/20 | 0.89 |
| ▸ | CASP7 | P55210 | 3/20 | 0.89 |
| ▸ | MAPT | P10636 | 3/20 | 0.89 |
| ▸ | CASP1 | P29466 | 2/20 | 0.89 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.89 |
| ▸ | TST | Q16762 | 2/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.89 |
| ▸ | HBB | P68871 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin SCHEMBL21805317 | 1.00 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL618997 | 1.00 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL367681 | 0.99 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL5477646 | 0.98 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL2241206 | 0.98 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL1085509 | 0.98 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL535031 | 0.97 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL27866166 | 0.97 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL50154 | 0.97 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL367680 | 0.96 | MEN1 (0.85) | MEN1KMT2AUSP2KDM4EHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365850-B2 | Water-miscible functional fluid, undiluted stock of water-miscible functional fluid, sterilizer for water-miscible functional fluid, and method of sterilizing water-miscible function fluid | YUSHIRO CHEMICAL INDUSTRY CO., LTD. (JP) | 2025-07-22 | — | — | US | claimed |
| CN-120053465-A | Preparation method of multivitamin injection | 山东力诺制药有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119326884-B | Nano-composite photosensitizer for transepithelial ion-introduced cornea collagen crosslinking, and preparation method and application thereof | 温州医科大学附属眼视光医院 | 2025-05-06 | — | — | CN | claimed |
| EP-4308161-B1 | OPHTHALMIC PREPARATIONS FOR PHOTO-CROSSLINKING REACTIONS | LIGI TECNOLOGIE MEDICALI S R L (IT) | 2025-04-30 | — | — | EP | claimed |
| CN-119769630-A | Traditional Chinese medicine anti-coccidiosis ruminant compound feed | 大庆市天赐饲料有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119701092-A | Collagen gel microsphere, and preparation method and application thereof | 深圳福楼拜生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-4500612-A1 | POLYSULFIDE-BASED AQUEOUS REDOX FLOW BATTERY WITH SOLUBLE ORGANIC CATALYST | The Chinese University of Hong Kong (HK) | 2025-02-05 | — | — | EP | claimed |
| CN-119326884-A | Nano-composite photosensitizer for transepithelial ion-introduced cornea collagen crosslinking, and preparation method and application thereof | 温州医科大学附属眼视光医院 | 2025-01-21 | — | — | CN | claimed |
| US-12206144-B2 | Polysulfide-based aqueous redox flow battery with soluble organic catalyst | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-01-21 | — | — | US | claimed |
| CN-119177564-A | Preparation method of metal-organic framework antibacterial non-woven material | 天津工业大学绍兴柯桥研究院 | 2024-12-24 | — | — | CN | claimed |
| US-20030216357-A1 | Compositions for improving lipid content in the blood | SANKYO COMPANY, LIMITED (JP) | 2003-11-20 | — | — | US | claimed |
| CN-1439298-A | Cellulosefree intestinal absorbing nutrient emulsion and its preparing method | HUARUI PHARMACEUTICAL CO LTD (CN) | 2003-09-03 | — | — | CN | claimed |
| CN-1439299-A | Intestinal absorbing fully nutrient emulsion for phymatostio patient | HUARUI PHARMACEUTICAL CO LTD (CN) | 2003-09-03 | — | — | CN | claimed |
| CN-1390118-A | Glucose and insulin liquid compositions for intravenous infusion | GANGAL HANAMARADDI T (IN) | 2003-01-08 | — | — | CN | claimed |
| EP-1231907-A2 | DEXTROSE AND INSULIN FLUID FORMULATION FOR INTRAVENOUS INFUSION | Gangal, Hanamaraddi T. (IN) | 2002-08-21 | — | — | EP | claimed |
| WO-2001035943-A2 | DEXTROSE AND INSULIN FLUID FORMULATION FOR INTRAVENOUS INFUSION | GANGAL HANAMARADDI T (IN) | 2001-05-25 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| CN-1140992-A | Flavin derivatives as anti-viral agents | RADOPATH LTD (GB) | 1997-01-22 | — | — | CN | claimed |
| EP-0739208-A1 | FLAVIN DERIVATIVES AS ANTI-VIRAL AGENTS | RADOPATH LIMITED (GB) | 1996-10-30 | — | — | EP | claimed |
| WO-1995011028-A1 | FLAVIN DERIVATIVES AS ANTI-VIRAL AGENTS | RADOPATH LIMITED (GB) | 1995-04-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216357-A1 | Compositions for improving lipid content in the blood | APOB, PPIP5K2, HMGCR | ADRB2 2760/4885ADRA1A 2685/4885MEN1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.